Psychedelic science in post-COVID-19 psychiatry
This commentary (2020) examines how the COVID-19 pandemic has affected the trajectory of clinical trials investigating psilocybin-treatment for a wide range of conditions, some of which are likely to become even more prevalent in post-COVID-19 clinical psychiatry. Although many of these clinical trials have been temporarily stagnant due to safety measures, ongoing efforts from large scale clinical studies of psilocybin will provide valuable information on its safety, dose optimization, and its efficacy compared to a conventional selective serotonin reuptake inhibitor (SSRI) and additional studies will elucidate whether it is safe to combine them with psilocybin therapy.
Authors
- John Kelly
- Veronica O'keane
Published
Abstract
Introduction: The medium- to long-term consequences of COVID-19 are not yet known, though an increase in mental health problems are predicted. Multidisciplinary strategies across socio-economic and psychological levels may be needed to mitigate the mental health burden of COVID-19. Preliminary evidence from the rapidly progressing field of psychedelic science shows that psilocybin therapy offers a promising transdiagnostic treatment strategy for a range of disorders with restricted and maladaptive habitual patterns of cognition and behaviour, notably depression, addiction and obsessive compulsive disorder. The COMPASS Pathways (COMPASS) phase 2b double-blind trial of psilocybin therapy in antidepressant-free, treatment-resistant depression (TRD) is underway to determine the safety, efficacy and optimal dose of psilocybin. Results from the Imperial College London Psilodep-RCT comparing the efficacy and mechanisms of action of psilocybin therapy to the selective serotonin reuptake inhibitor (SSRI) escitalopram will soon be published. However, the efficacy and safety of psilocybin therapy in conjunction with SSRIs in TRD is not yet known. An additional COMPASS study, with a centre in Dublin, will begin to address this question, with potential implications for the future delivery of psilocybin therapy. While at a relatively early stage of clinical development, and notwithstanding the immense challenges of COVID-19, psilocybin therapy has the potential to play an important therapeutic role for various psychiatric disorders in post-COVID-19 clinical psychiatry.
Research Summary of 'Psychedelic science in post-COVID-19 psychiatry'
Introduction
Crises such as the COVID-19 pandemic provoke a wide range of psychological reactions, and the authors highlight predictions of an increased burden of mental health problems, especially among vulnerable groups. They position multidisciplinary responses across socioeconomic and psychological levels as necessary to mitigate this burden and note that early clinical data indicate psilocybin therapy could be a promising transdiagnostic option for disorders marked by restricted or maladaptive cognitive and behavioural habitual patterns, notably depression, addiction and obsessive–compulsive disorder. Kelly and colleagues set out to summarise recent advances in psychedelic science relevant to post-COVID-19 psychiatry, emphasising mechanistic findings, emerging clinical trial evidence and practical considerations for delivering psilocybin therapy during and after the pandemic. The paper describes ongoing and planned clinical trials (including COMPASS and the Imperial College Psilodep-RCT), discusses biological and imaging studies that inform mechanisms of action, and raises questions about safety, acceptability and the implications of concomitant antidepressant use.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Create a free account to open full-text PDFs.
Study Details
- Study Typemeta
- Journal
- Compound
- Topics
- Authors
- APA Citation
Kelly, J. R., Crockett, M. T., Alexander, L., Haran, M., Baker, A., Burke, L., Brennan, C., & O’Keane, V. (2021). Psychedelic science in post-COVID-19 psychiatry. Irish Journal of Psychological Medicine, 38(2), 93-98. https://doi.org/10.1017/ipm.2020.94
References (37)
Papers cited by this study that are also in Blossom
Barrett, F. S., Doss, M. K., Sepeda, N. D. et al. · Scientific Reports (2020)
Barrett, F. S., Krimmel, S. R., Griffiths, R. R. et al. · NeuroImage (2020)
Bonson, K. R. · Neuropsychopharmacology (1996)
Rodríguez-Fornells, A., Ribeiro, S., Sanches, R. F. et al. · European Neuropsychopharmacology (2015)
Carbonaro, T. M., Bradstreet, M. P., Barrett, F. S. et al. · Journal of Psychopharmacology (2016)
Carhart-Harris, R. L., Bolstridge, M., Rucker, J. et al. · Lancet Psychiatry (2016)
Carhart-Harris, R. L., Friston, K. J. · Pharmacological Reviews (2019)
Carhart-Harris, R. L., Nutt, D. J. · Journal of Psychopharmacology (2017)
Erritzoe, D., Roseman, L., Nour, M. R. et al. · Acta Psychiatrica Scandinavica (2018)
Garcia-Romeu, A., Davis, A. K., Fire Erowid et al. · Journal of Psychopharmacology (2019)
Show all 37 referencesShow fewer
Gonza ´lez-Maeso, J., Weisstaub, N. V., Zhou, M. et al. · Neuron (2007)
Griffiths, R. R., Richards, W. A., Mccann, U. et al. · Journal of Psychopharmacology (2006)
Halpern, J. H., Sherwood, A. R., Hudson, J. I. et al. · Biological Psychiatry (2005)
Jefsen, O., Højgaard, K., Christiansen, S. L. et al. · Acta Neuropsychiatrica (2019)
Kettner, H., Gandy, S., Haijen, E. C. H. M. et al. · International Journal of Environmental Research and Public Health (2019)
Kraehenmann, R., Preller, K. H., Scheidegger, M. et al. · Biological Psychiatry (2015)
Kuypers, K. P. C. · Medical Hypotheses (2019)
Lewis, C. R., Preller, K. H., Braden, B. B. et al. · Biomedicines (2020)
Lord, L. D., Expert, P., Atasoy, S. et al. · NeuroImage (2019)
Ly, C., Greb, A. C., Cameron, L. P. et al. · Cell Reports (2018)
Martinotti, G., Santacroce, R., Pettorruso, M. et al. · Brain Sciences (2018)
Mason, N. L., Kuypers, K. P. C., Reckweg, J. et al. · Neuropsychopharmacology (2020)
Meinhardt, M. W., Güngör, C., Skorodumov, I. et al. · Neuropsychopharmacology (2020)
Mertens, L. J., Wall, M. B., Roseman, L. et al. · Journal of Psychopharmacology (2020)
Morales-García, J. A., de la Fuente Revenga, M., Alonso-Gil, S. et al. · Scientific Reports (2017)
Moreno, F. A., Wiegand, C. B., Taitano, E. K. et al. · Journal of Clinical Psychiatry (2006)
Nutt, D. J., Erritzoe, D., Carhart-Harris, R. L. · Cell (2020)
Pokorny, T., Preller, K. H., Kraehenmann, R. et al. · European Neuropsychopharmacology (2016)
Preller, K. H., Herdener, M., Pokorny, T. et al. · Current Biology (2017)
Preller, K. H., Pokorny, D., Hock, A. et al. · PNAS (2016)
Roseman, L., Demetriou, L., Wall, M. B. et al. · Neuropharmacology (2018)
Smigielski, L., Scheidegger, M., Kometer, M. et al. · NeuroImage (2019)
Strajhar, P., Schmid, Y., Liakoni, E. et al. · Journal of Neuroendocrinology (2016)
Studerus, E., Gamma, A., Kometer, M. et al. · PLOS ONE (2012)
Szabo, A. · Frontiers in Immunology (2015)
Varley, T. F., Carhart-Harris, R., Roseman, L. et al. · NeuroImage (2020)
Weston, N. M., Gibbs, D., Bird, C. I. V. et al. · Depression and Anxiety (2020)
Cited By (5)
Papers in Blossom that reference this study
Bouso, J. C., Révész, D., Ona, G. et al. · Scientific Reports (2023)
Dursun, S. M., Kelly, J. R., Gillan, C. M. et al. · Frontiers in Psychiatry (2021)
Corrigan, K., Haran, M., Mccandliss, C. et al. · Irish Journal of Medical Science (2021)
Carhart-Harris, R. L., Wagner, A. C., Agrawal, M. et al. · Journal of Psychopharmacology (2021)
Kettner, H., Rosas, F. E., Timmermann, C. et al. · Frontiers in Pharmacology (2021)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.